Attovia Therapeutics, Inc. Common Stock (NASDAQ:ATTO) — Market Cap & Net Worth
Market Cap & Net Worth: Attovia Therapeutics, Inc. Common Stock (ATTO)
Attovia Therapeutics, Inc. Common Stock (NASDAQ:ATTO) has a market capitalization of $1.03 Billion ($1.03 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8765 globally and #2516 in its home market, demonstrating a -7.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Attovia Therapeutics, Inc. Common Stock's stock price $23.70 by its total outstanding shares 45651262 (45.65 Million). Also see Attovia Therapeutics, Inc. Common Stock balance sheet assets for a full breakdown of the balance sheet.
Attovia Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Attovia Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $1.08 Billion to $1.08 Billion (0.00% CAGR). Also see ATTO operating cash flow for how efficiently the company converts equity into cash flow.
Attovia Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Attovia Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ATTO share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ATTO by Market Capitalization
Companies near Attovia Therapeutics, Inc. Common Stock in the global market cap rankings as of September 17, 2026. Review ATTO tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Attovia Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Attovia Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Attovia Therapeutics, Inc. Common Stock's market cap moved from $1.08 Billion to $ 1.08 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Attovia Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Billion USD |
| MoneyControl | $1.03 Billion USD |
| MarketWatch | $1.03 Billion USD |
| marketcap.company | $1.03 Billion USD |
| Reuters | $1.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of… Read more